Showing results (1-10 of 122) with videos related to
Sort By:
Pageof 13
Cancer Journal (Sudbury, Mass.)|September 20, 2017
Targeting Histone Acetylation: Readers and Writers in Leukemia and CancerChristopher B Benton, Warren Fiskus, Kapil N BhallaHematology/Oncology Clinics of North America|September 27, 2012
Role of additional novel therapies in myeloproliferative neoplasmsWarren Fiskus, Siddhartha Ganguly, Suman Kambhampati, et al.Advances in Cancer Research|October 24, 2012
HDAC inhibitors and chaperone functionRekha Rao, Warren Fiskus, Siddhartha Ganguly, et al.Oncotarget|December 13, 2012
Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancerSreedhar Venkannagari, Warren Fiskus, Karissa Peth, et al.Molecular Cancer Therapeutics|May 14, 2011
Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damageKyungsoo Ha, Warren Fiskus, Rekha Rao, et al.Blood Cancer Journal|March 23, 2021
EVI1 dysregulation: impact on biology and therapy of myeloid malignanciesChristine Birdwell, Warren Fiskus, Tapan M Kadia, et al.Molecular Cancer Therapeutics|March 1, 2013
Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.Proceedings of the National Academy of Sciences of the United States of America|April 10, 2013
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagyYonghua Yang, Warren Fiskus, Bao Yong, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2005
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignanciesKapil N BhallaPageof 13